Original ArticleEfficacy and tolerability of coenzyme A vs PANTETHINE (cas 138148-35-3) for the treatment of patients with hyperlipidemia: A randomized, double-blind, multicenter study
-
Add time:08/18/2019 Source:sciencedirect.com
BackgroundNew, safer, and more effective agents to treat hyperlipidemia and thereby prevent cardiovascular events are under research.
We also recommend Trading Suppliers and Manufacturers of PANTETHINE (cas 138148-35-3). Pls Click Website Link as below: cas 138148-35-3 suppliers
Prev:Original articleComparison of the effects of PANTETHINE (cas 138148-35-3) and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure
Next:Review articleTreatment of hyperlipoproteinemia with PANTETHINE (cas 138148-35-3): A review and analysis of efficacy and tolerability) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PANTETHINE (cas 138148-35-3) stimulates lipolysis in adipose tissue and inhibits cholesterol and fatty acid synthesis in liver and intestinal mucosa in the normolipidemic rat08/25/2019
- BBA reportModulation of HMG-CoA reductase activity by pantetheine/PANTETHINE (cas 138148-35-3)08/24/2019
- Research paperEffects of PANTETHINE (cas 138148-35-3) on in-vitro peroxidation of low density lipoproteins☆08/23/2019
- PANTETHINE (cas 138148-35-3), a somatostatin depleting agent, increases food intake in rats☆08/22/2019
- Research paperPANTETHINE (cas 138148-35-3) lipomodulation: evidence for cysteamine mediation in vitro and in vivo08/21/2019
- Reduction of PANTETHINE (cas 138148-35-3) in rabbit ocular lens homogenate08/20/2019
- Review articleTreatment of hyperlipoproteinemia with PANTETHINE (cas 138148-35-3): A review and analysis of efficacy and tolerability08/19/2019
- Original articleComparison of the effects of PANTETHINE (cas 138148-35-3) and fursultiamine on plasma levels of adrenocorticotropic hormone and neuropeptide Y under continual stress exposure08/17/2019
